FIGURE 3 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Year: 2023
Type: other
Abstract: Baseline (up) and after treatment (down) images in Patient A (Cisplatin-Olaparib arm) and B (Olaparib arm), respectively, showing dramatic tumor volumetric decrease. Both patients had SD on imaging based on RECIST. Representative immunofluorescence (IF) images at baseline (up) and after treatment (down), highlighting changes in Ki67 (red), PD-L1 (white), STING (magenta) in tumor. Nuclei (blue) and cytokeratin (green) are also shown. A posttreatment decrease in Ki-67 (measured by QIF) was noticed in both patients.
Authors: Myrto Moutafi, Georgia-Angeliki Koliou, George Papaxoinis, Panagiota Economopoulou, Ioannis Kotsantis, Maria Gkotzamanidou, Maria Anastasiou, Dimitrios Pectasides, Efthymios Kyrodimos, Alexander Delides, Evangelos Giotakis, Nikolaos G. Papadimitriou, Ioannis G. Panayiotides, Christos Perisanidis, Aileen I. Fernandez, Vasiliki Xirou, Christos Poulios, Eleni Gagari, Vesal Yaghoobi, Niki Gavrielatou, Saba Shafi, Thazin Nwe Aung, Andromachi Kougioumtzopoulou, Vassilis Kouloulias, Konstantinos Palialexis, Stavros Gkolfinopoulos, Areti Strati, Evi Lianidou, George Fountzilas, David L. Rimm, Periklis G. Foukas, Amanda Psyrri
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4385738046